ATS 2024 Final Program

Click on the session title to view the speakers

151

MONDAY • MAY 20

P1484 Pleuro-subcutaneous Fistula: A Complication of Chest Wall Trauma P1485 Hamman Syndrome With Rare Feature of Pneumorrhachis - An Unusual Complication of Polysubstance Abuse and E-vaping P1486 Pneumomediastinum: A Rare Complication of Dental Extraction

P1190 Time-course Changes in Serum Surfactant Protein-D Levels Before and After Acute Exacerbation in Idiopathic Pulmonary Fibrosis P1191 Idiopathic Pulmonary Fibrosis Patients: Clinical Usefulness of KL-6 Levels at Baseline and Follow-up P1192 Standardisation of BAL Cell Fraction Assessment Using AI Models P1193 Starship: Study of Telomeres and Role of Sex Hormones in Pulmonary Fibrosis P1194 Telomere Shortening in Patients With Familial Fibrotic Hypersensitivity Pneumonitis P1195 Accelerating Diagnosis, Management, and Treatment of Pulmonary Fibrosis and Telomere Biology Disorders: Publication and Dissemination of Diagnosis and Management Guidelines P1196 Association Between Pulmonary Function Test and Deep Learning Quantitative Lung Fibrosis Score in Subjects With Interstitial Lung Diseases P1197 3D-CT Assessment of Normal Upper-lobe Lung Volume in Patients With Idiopathic Pleuroparenchymal Fibroelastosis P1198 Automated AI Detection of Clinical Interstitial Lung Disease by CT in the COPDGene Trial P1199 Artificial Intelligence-based Quantitation of CT Patterns and Its Clinical Impacts in Patients With Idiopathic Pleuroparenchymal Fibroelastosis Semi-automated Analysis and Artificial Intelligence (AI) in Diffuse Cystic Lung Diseases P1201 Using Imaging to Predict, Identify, and Monitor Progression of Interstitial Lung Disease: Consensus Findings From a Modified Delphi Study P1202 Endobronchial Optical Coherence Tomography Imaging Detects Micro-progression as a Novel Method for Monitoring Disease Progression in IPF Proteinase-3 (ELP-3) Is a Serological Biomarker to Distinguish Fibrotic From Non-fibrotic Hypersensitivity Pneumonitis P1200 Cyst Volume and Number Determined by P1203 A Specific Elastin Peptide Degraded by

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B46 UP AND COMING: ILD BIOMARKERS 9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area K (Hall H, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1182 High Density Lipoproteins, Disease Severity and Clinical Outcomes in Idiopathic Pulmonary Fibrosis P1183 Development of a Multi-biomarker Assay for Serum Proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC) P1184 Mast-cell Expressed Membrane Protein-1 (MCEMP1) Is Detected in Plasma and Predicts Outcomes in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis Response in Connective Tissue-related Interstitial Lung Disease P1186 Clinical Significance of Serum Syndecan-4 in Patients With Drug-induced Interstitial Lung Disease P1187 Characteristics of Pulmonary Sarcoidosis Patients With Elevated Soluble Interleukin-2 Levels P1188 Urine TSC2 Mutation and Treatment Response in Sporadic Lymphangioleiomyomatosis: A Prospective Cohort Study P1189 The Causal Relationship Between Gut Microbiota and Idiopathic Pulmonary Fibrosis: A Two-sample Mendelian Randomization Study P1185 Use of Biomarkers Can Predict Treatment

ATS 2024 Conference Program • San Diego, CA